Immunotherapy, including tumor infiltrating lymphocyte therapy, interleukin-2, and the CTLA inhibitor ipilimumab, promotes T cell activation and survival in order to augment the immune response against neoplastic cells, but inadvertently tips the balance toward autoimmunity including the development of VKH [80–82]. This evidence concerns the gene IL2 and neoplasm.